Key facts
- This page summarizes Doug Samuelson's Form 4 filing for Kairos Pharma, LTD. (KAPA).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 26 Nov 2025, 17:24.
Doug Samuelson - 08 Oct 2025 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)
- Signature
- /s/ Doug Samuelson
- Issuer symbol
- KAPA
- Transactions as of
- 08 Oct 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 26 Nov 2025, 17:24:13 UTC
- Previous filing
- 25 Nov 2024
- SEC
- View on sec.gov
Key filing fact
Doug Samuelson filed Form 4 for Kairos Pharma, LTD. (KAPA) on 26 Nov 2025.
Change
- Previous filing in this sequence was filed on 25 Nov 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001943326
Primary reporting owner
Samuelson Doug
- Relationship
- Chief Financial Officer
- Address
- C/O KAIROS PHARMA, LTD., 2355 WESTWOOD BLVD, #139, LOS ANGELES
- Signature
- /s/ Doug Samuelson
- Signature date
- 26 Nov 2025
Transactions Table
KAPA
transaction
COMMON STOCK
Award
- Transaction value
- $0
- Shares
- +152,672
- Change %
- +109%
- Price
- $0.000000
- Shares after
- 293,039
- Date
- 08 Oct 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. |
| F2 | Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting. |